Indian Immunologicals Achieves Record Revenue of Rs1,586 Crore in FY26

Indian Immunologicals Limited has reported its highest-ever annual revenue of ?1,586 crore for the financial year 2025–26, marking a major milestone in the company’s growth. The strong performance reflects increasing demand for vaccine manufacturing, animal healthcare, and human healthcare products across India.

Based in India, the company has steadily expanded its presence in the Indian vaccine market through continuous investment in research and development, manufacturing, and product innovation. The latest revenue figures highlight the company’s growing influence in the healthcare industry and its ability to meet rising demand.

A large part of the company’s success comes from its leadership in livestock vaccines. Indian Immunologicals is widely known for producing Foot and Mouth Disease vaccines, which play an important role in protecting animal health and supporting the agriculture sector. At the same time, its human healthcare division continues to grow, especially through anti-rabies vaccines, which remain in high demand across the country.

Also Read: Alembic Secures USFDA Nod for Fingolimod Capsules in US Market

The company’s steady growth has been driven by rising awareness about disease prevention, stronger vaccination programs, and improved healthcare access in both rural and urban regions. A broader product portfolio and better manufacturing efficiency have also supported business expansion.

Indian Immunologicals continues to invest in biopharmaceutical growth by strengthening its scientific research capabilities and developing new healthcare solutions. Its teams are focused on expanding production and improving supply chains to meet future market requirements.

Industry experts believe the company’s strong financial performance reflects the increasing importance of public health programs and vaccine production in India. Government initiatives focused on disease prevention, livestock welfare, and healthcare access are expected to create long-term opportunities for vaccine manufacturers.

With this record-breaking achievement, Indian Immunologicals has strengthened its position as a leader in the healthcare industry India segment. The company’s growth also reflects the rising importance of pharmaceutical innovation in building a stronger healthcare ecosystem.

As India’s healthcare sector continues to expand, Indian Immunologicals is expected to play a major role in supporting national vaccination efforts and improving public health outcomes.